About this article Cite this article Drucker, D.J
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Although retatrutide is showing promising results in clinical trials, it has not yet been FDA approved, so conclusions cant be made around it being the best weight loss solution
For users who are already overwhelmed by managing their GLP-1 dosing protocol , the simplicity of Replenza has real value
Whether this is due to the limited increase in GLP-1 from 3.3 pM 0.5 pM (before LFD) to 3.6 pM 0.9 pM (after LFD) should be investigated in future studies
My personal goal for trying them out is to see if I notice improvements in my energy levels, digestion, and just overall feeling of lightness